Pfenex Set to Join Russell 2000® Index
June 22 2018 - 5:00PM
Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and
licensing biotechnology company focused on leveraging its Pfenex
Expression Technology® to improve protein therapies for unmet
patient needs, today announced it is set to join the small-cap
Russell 2000® Index at the conclusion of the Russell U.S. Indexes
annual reconstitution, effective after the U.S. market opens on
June 25th, according to the final list of additions posted on June
22nd.
Eef Schimmelpennink, the Chief Executive Officer of Pfenex,
stated, "We are very pleased to be included in the Russell 2000®
Index. This is an important milestone for the Company and
represents an opportunity to further increase our visibility within
the investment community."
Indexes provided by FTSE Russell, a leading global index
provider, are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $6 trillion in assets are
benchmarked against the Russell US Indexes.
For more information on the Russell 2000® Index and the Russell
US Indexes reconstitution, go to the "Russell Reconstitution"
section on the FTSE Russell website.
Pfenex investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (http://www.pfenex.com),
our investor relations website (http://pfenex.investorroom.com),
press releases, SEC filings, public conference calls, corporate
Twitter account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline), and
LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with our disclosure
obligations under Regulation FD. We encourage our investors
and others to monitor and review the information we make public in
these locations as such information could be deemed to be material
information. Please note that this list may be updated from
time to time.
About Pfenex Inc.Pfenex is a clinical-stage
development and licensing biotechnology company focused on
leveraging its Pfenex Expression Technology® to improve protein
therapies for unmet patient needs. Using the patented Pfenex
Expression Technology platform, the Company has created an advanced
pipeline of therapeutic equivalents, vaccines, biologics and
biosimilars. The Company's lead product candidates are PF708, a
therapeutic equivalent candidate to Forteo® (teriparatide) for the
treatment of osteoporosis, and its novel anthrax vaccine
candidates, Px563L and RPA563, funded through an advanced
development contract with the U.S. government. In addition, the
Company is developing hematology/oncology products in collaboration
with Jazz Pharmaceuticals. Furthermore, the Company’s pipeline
includes biosimilar candidates to Lucentis® and Neulasta®.
About FTSE Russell:FTSE Russell is a leading
global index provider creating and managing a wide range of
indexes, data and analytic solutions to meet client needs across
asset classes, style and strategies. Covering 98% of the investable
market, FTSE Russell indexes offer a true picture of global
markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16.2
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group. For more information, visit
www.ftserussell.com.
Contacts:Susan A. KnudsonChief Financial
OfficerPfenex, Inc.sknudson@pfenex.com